137 related articles for article (PubMed ID: 34249438)
1. Targeting ERK combined with apatinib may be a promising therapeutic strategy for treating oral squamous cell carcinoma.
Zhao TC; Liang SY; Zhou ZH; Ju WT; Zhang ZY; Zhu DW; Zhong LP
Am J Cancer Res; 2021; 11(6):2960-2974. PubMed ID: 34249438
[TBL] [Abstract][Full Text] [Related]
2. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.
Qiu H; Li J; Liu Q; Tang M; Wang Y
Cell Cycle; 2018; 17(10):1235-1244. PubMed ID: 29886786
[TBL] [Abstract][Full Text] [Related]
3. Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway.
Meng X; Wang H; Zhao J; Hu L; Zhi J; Wei S; Ruan X; Hou X; Li D; Zhang J; Yang W; Qian B; Wu Y; Zhang Y; Meng Z; Guan L; Zhang H; Zheng X; Gao M
Front Oncol; 2020; 10():217. PubMed ID: 32219060
[No Abstract] [Full Text] [Related]
4. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
5. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma.
Liu K; Ren T; Huang Y; Sun K; Bao X; Wang S; Zheng B; Guo W
Cell Death Dis; 2017 Aug; 8(8):e3015. PubMed ID: 28837148
[TBL] [Abstract][Full Text] [Related]
6. Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma.
Yu X; Fan H; Jiang X; Zheng W; Yang Y; Jin M; Ma X; Jiang W
Oncol Lett; 2020 Oct; 20(4):52. PubMed ID: 32788939
[TBL] [Abstract][Full Text] [Related]
7. Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α-AKT-mTOR pathway in esophageal squamous cell carcinoma.
Wang YM; Xu X; Tang J; Sun ZY; Fu YJ; Zhao XJ; Ma XM; Ye Q
Cell Biosci; 2021 Jul; 11(1):124. PubMed ID: 34229754
[TBL] [Abstract][Full Text] [Related]
8. Apatinib strengthens the anti-tumor effect of cisplatin in thyroid carcinoma through downregulating VEGFR2.
Hu Y; Zhou N; Wang R
J BUON; 2021; 26(2):613-619. PubMed ID: 34077013
[TBL] [Abstract][Full Text] [Related]
9. Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis.
Deng M; Zha J; Zhao H; Jia X; Shi Y; Li Z; Fu G; Yu L; Fang Z; Xu B
Exp Cell Res; 2020 May; 390(1):111934. PubMed ID: 32126236
[TBL] [Abstract][Full Text] [Related]
10. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
Huang M; Huang B; Li G; Zeng S
BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
[TBL] [Abstract][Full Text] [Related]
11. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.
Chen L; Cheng X; Tu W; Qi Z; Li H; Liu F; Yang Y; Zhang Z; Wang Z
Cell Oncol (Dordr); 2019 Oct; 42(5):679-690. PubMed ID: 31325096
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling.
Cai X; Wei B; Li L; Chen X; Yang J; Li X; Jiang X; Lv M; Li M; Lin Y; Xu Q; Guo W; Gu Y
Onco Targets Ther; 2020; 13():11031-11044. PubMed ID: 33154652
[TBL] [Abstract][Full Text] [Related]
13. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
14. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.
Peng H; Zhang Q; Li J; Zhang N; Hua Y; Xu L; Deng Y; Lai J; Peng Z; Peng B; Chen M; Peng S; Kuang M
Oncotarget; 2016 Mar; 7(13):17220-9. PubMed ID: 26967384
[TBL] [Abstract][Full Text] [Related]
15. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway.
Wang Y; Deng M; Chen Q; Li Y; Guo X; Shi P; He L; Xie S; Yu L; Zhang H; Xu B
Eur J Pharmacol; 2019 Jan; 843():145-153. PubMed ID: 30423319
[TBL] [Abstract][Full Text] [Related]
16. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
Liao J; Jin H; Li S; Xu L; Peng Z; Wei G; Long J; Guo Y; Kuang M; Zhou Q; Peng S
J Exp Clin Cancer Res; 2019 Nov; 38(1):454. PubMed ID: 31694662
[TBL] [Abstract][Full Text] [Related]
17. Apatinib Inhibits Bladder Cancer through Suppression of the VEGFR2- PI3K-AKT Signaling Pathway as Revealed by Network Pharmacology and
Wang W; Chen L; Yang J; Hu D; Yang Y; Dong T; Long X; Zou Y; Li J; Ma X; Dai W; Zhou X; Chen B; Su Y
Comb Chem High Throughput Screen; 2023; 26(13):2380-2392. PubMed ID: 36852790
[TBL] [Abstract][Full Text] [Related]
18. Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway.
Remadevi V; Jaikumar VS; Vini R; Krishnendhu B; Azeez JM; Sundaram S; Sreeja S
Phytomedicine; 2024 May; 130():155721. PubMed ID: 38788395
[TBL] [Abstract][Full Text] [Related]
19. Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells.
Sun X; Li J; Li Y; Wang S; Li Q
Oxid Med Cell Longev; 2020; 2020():3145182. PubMed ID: 32509141
[TBL] [Abstract][Full Text] [Related]
20. Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway.
Wei B; Wang Y; Wang J; Cai X; Xu L; Wu J; Wang Y; Liu W; Gu Y; Guo W; Xu Q
Cancer Cell Int; 2020; 20():198. PubMed ID: 32514243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
